NBSE - Earnings call transcript Q4 2017 | NeuBase Therapeutics Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. And welcome to the Ohr Pharmaceutical Company’s Fiscal Year 2017 Conference Call. At this time, all participants are in a listen-only-mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. of Director Managing Amdt, LifeSci Advisors. Paul you. Thank

may You begin.

Paul Amdt

fiscal everyone. you, the issued Ohr and for financial XX, morning Melissa, good This the highlights a review, for year morning ended the September XXXX. Thank results in year press release with

did call this release, not be and replay is the being available it website company's available. receive on will section webcast Relations the yet at you is on If Investor www.ohrpharmaceutical.com. This a

prospects, Friday, call release As difficult statements contain a current expression the not forward-looking. conference identify as variations forward-looking information with on belief, as statements, reminder, Such and to are but satisfaction date. of XX, of filings forward-looking Financial with news forward-looking statement statements or intend, general involve Dr. the that is The and These statements does uncertainties such that Form today’s which expect, regarding new Words as conference on their risks, reflecting information competitive that anticipate mean similar optimism, well sir. plan, XXXX. Chief and be this detail circumstances shortly, in and Dr. I to marketplace, no absence assumptions words demand in for company's with Backenroth, predict. additional as Several studies, future trials, Executive ahead, are in on of could include and Mr. release guarantee could to developments, to and statements any December in speak today's like to XX-Q, such clinical our to the forward-looking performance our conditions. our supply over are statements. obligation changes develop such well forward-looking from XX-K, results company the legislative, Report Chief and successfully in partnership and our Officer; Officer. conclude ability technological Jason turn products, differences regulatory ability resources publicly materially not as abilities these SEC. of our company With are the factors or Form conclude financial raise contained after sufficient contribute Sam call, agreements, rapid to of the will actual the funds to and go Participating differ any cause change products, Slakter, to a that to the Annual Please available scientific These in call only future described perform economic negotiate today's this update our the as strategic company's undertakes those us, that, the Slakter. call factors success not filed

Jason Slakter

Good Paul. approach characteristics Thank Ohr the standard for mechanism you MAKO of of understand in the retinal become impact believe as Phase more MAKO put you, and exciting we eagerly population. considerable morning end for at has and time about a what of well the from into disease. learned together of the the and new thought We care study what with prior significant new a establish in treatment Squalamine’s first action, decade design study of the incorporating we AMD as of than that we X on This year. early Squalamine We remain for trial the everyone and next potential topline a very product focused joining to the the XXXX everyone thank wet-AMD await the the today. in us results is as Squalamine opportunity

critical study, selection patient prior that combination design study results prospectively present believe neovascularization the enroll with therapy combination elements occult of of on important size enriched that Squalamine is analysis, occult the that therapy. helped that combination patients factor visual acuity on maybe the the the properties all we and our determine was in One unique from in potential greatest visual the impact de-risked visual there which population strong Patient Squalamine see or an will Based start drug choroidal driving Phase we us is we a rationale Analysis think most the outcomes not benefits we for this the trial. treatment of candidates. of it best the influencing the was CNV X from of to is therapy. acuity benefit of enrolled this of MAKO the the in Furthermore, important Squalamine most population feel based has impact at we the the wet-AMD.

in of in these remain Squalamine in in partners included Directors. readout. Board financings the most XXXX We several MAKO $XX.X with of and We action study calendar most completed acuity trial than decision participation amend In was Phase disease. XXXX, angiogenic offering million. X existing where two three-line planned. goal earlier against was business and led raising study is near and of of and proportion year and see The our this for We a We topical regarding of visual of More further activity the for investors that the data data considerable will for members and a discussions study gainers management MAKO the million confirm multiple improvement subjects million to where the net a completing senior impact total by term benefit XXX the sub-group reporting suppressive goal this mean that the of a of an it route group study, discussions. combined administration fiscal recent which addition the represents therapy Squalamine of company's is continue more twice to the in year of in is by last active readout a having efficacious. its topline than delivery the in early strategic development interest. in pharmaceutical believe earlier and sustained benefits April December inter-cellular and targets, which daily net both to these the with than patients made side chronic demonstrate Squalamine’s a enables identified enrolled in year the of almost MAKO It previously $X.X potential and $XX.X of in to number the MAKO

XXXX, including We have the report clinical rules. the and days our am have compliance are stock, to data the above based price NASDAQ happy regained XX we the into and readout. funded common of the on I level listing of trial MAKO trading that consecutive yesterday's also completion very been April closing $X for therefore with

conforming letter receive financials. this to to from the Sam few Sam? like We With of for expect handover fact. next the our days to summary in I’d that, a NASDAQ a call

Sam Backenroth

Jason. you, Thank

million, administrative expenses, $XX.X XXXX expenses in of million and consisting in consisting and depreciation million, in year ended of the operating research total amortization. total same $X.X million $XX.X general $X.X September and For XX, This of development million administrative general depreciation million compares expenses, approximately and and were expenses million of the $XX.X to approximately of $X.X expenses, operating in period research XXXX. and amortization and and approximately in million in development $XX.X $X.X expenses

prior approximately we of At XX, year per company the $X.XX $XX.X loss approximately to net million ended share year equivalents the year. had XX, $X.XX to million. XX For a cash approximately and $XX.X of XXXX, loss compares This million million or of the $XX.X September reported in or at per September September XXXX. $XX.X of approximately XXXX, compared cash fiscal a net share,

completes XX-K, now will which more call review refer to financials. be of please final for That of our the I to to remarks. hand back For detailed description my Jason? shortly. the a over like filed financials, the would Jason

Jason Slakter

today's do not we involved of express in particularly do. thanks everyone from want take this Thanks the the proximity call are I the study who Sam. in the in call program. people very MAKO for this usually on progress Ohr. data at Unfortunately, and to receiving critical MAKO thank following due study, our going to as to want us to take again to patients participated opportunity also questions participating the clinical this to we my I most

We XXXX. the continue help we look from patients to and excited updating of of the the be to wet-AMD the results community MAKO about suffering study investment receive forward once early in to potential Squalamine

team Ohr, you. peaceful Year. of I to holiday half all healthy the entire New a you the On and want happy at season a and wish Thank

Operator

concludes Thank today's teleconference. you. This

disconnect Thank your time. at You this participation. may your you for lines

NeuBase Therapeutics (NBSE) 15 Dec 172017 Q4 Earnings call transcript